Geron
Corp. (Nasdaq: GERN) entered a license and collaboration agreement with
Janssen Biotech to develop and commercialize Geron's telomerase
inhibitor imetelstat. The stock price climbed 56 cents to $2.87.
Geron to license imetelstat
November 14, 2014 at 12:04 PM EST
